EUMAR TECHNOLOGY LIMITED
Company number 01884830 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Credit Analysis: Eumar Technology Limited
1. Credit Opinion: APPROVE
Reasoning: Eumar Technology Limited presents a strong credit profile supported by substantial net assets (£3.94M), minimal leverage (current liabilities of just £323K against £4.68M total assets), and demonstrated profitability evidenced by £624,570 retained profit in FY2025. The company operates in a specialist niche (clean room technology and medical device manufacturing) with a 40-year trading history, providing significant business resilience. The only notable concern is the sharp increase in debtors year-on-year, which warrants monitoring but does not undermine the overall strong creditworthiness.
2. Financial Strength
Balance Sheet Summary (FY2025):
| Metric | FY2025 | FY2024 | Movement |
|---|---|---|---|
| Net Assets | £3,941,269 | £3,317,799 | +£623,470 |
| Total Assets | £4,681,431 | £4,239,516 | +£441,915 |
| Total Liabilities | £323,446 | £493,707 | -£170,261 |
| Shareholders' Funds | £3,941,269 | £3,317,799 | +£623,470 |
Key Observations:
- Exceptionally low leverage: Current liabilities represent just 6.9% of total assets. There is no visible long-term debt on the balance sheet.
- Strong equity base: Net assets have grown from £599,612 (2018) to £3,941,269 (2025), representing compound growth of approximately 31% annually over seven years. This demonstrates sustained value creation.
- Gearing: Effectively nil. The company operates with virtually no external debt financing, relying on retained profits and working capital.
- Asset composition: Fixed assets of £1.96M (predominantly plant, machinery, and long leasehold) support manufacturing operations. The company invested £302,668 in additions during FY2025, indicating ongoing capital expenditure.
- Provisions: £408,466 in provisions exists (largely unchanged from FY2024's £416,760). While material, these have been stable and likely relate to deferred consideration or known liabilities rather than uncertain obligations.
Trajectory: Positive. Net assets have grown consistently, with the exception of a dip in FY2022. The FY2025 profit of £624,570 represents a healthy return.
3. Cash Flow Assessment
Liquidity Position:
| Metric | FY2025 | FY2024 |
|---|---|---|
| Current Assets | £2,723,851 | £2,186,826 |
| Current Liabilities | £323,446 | £493,707 |
| Current Ratio | 8.42x | 4.43x |
| Quick Assets (ex-stock) | £2,271,809 | £1,620,746 |
| Quick Ratio | 7.02x | 3.28x |
| Cash | £681,761 | £946,562 |
Working Capital Analysis:
- Current ratio of 8.42x is exceptionally strong and well above the typical benchmark of 1.5x for manufacturing businesses. The company has ample headroom to meet short-term obligations.
- Cash position has decreased from £946,562 to £681,761, a reduction of £264,801. However, this appears to be driven by capital investment (£302,668 in tangible asset additions) rather than operational cash burn.
- Debtors have increased dramatically: From £674,184 to £1,590,048 (+136%). This is the most significant concern in the financial profile. While this may reflect genuine revenue growth, it could also indicate:
- Extended payment terms to customers
- Collection difficulties
- Concentration risk with a single large customer
Without turnover data (filleted accounts), it is impossible to calculate debtor days, but the absolute increase warrants investigation.
- Stock levels have decreased from £566,080 to £452,042, suggesting improved inventory management or demand outstripping supply replenishment.
Cash Flow Trajectory: The historical cash position shows significant volatility (ranging from £875 in 2017 to £2.43M in 2021), which appears correlated with major balance sheet restructuring around FY2019-2020. Since the restructuring, cash has stabilised at a more sustainable level of £640K-£946K.
4. Monitoring Points
| Metric | Target/Threshold | Rationale |
|---|---|---|
| Debtors level | Track quarterly; investigate if exceeds £2M | 136% YoY increase is unusual; need to understand whether this reflects growth or collection risk |
| Debtor days | Request turnover data to calculate; benchmark against sector | Critical to assess whether debtor growth is proportionate to revenue |
| Cash position | Minimum £500K | Current level adequate but declining trend needs watching |
| Current ratio | Maintain above 2.0x | Currently 8.4x; significant buffer exists |
| Provisions | Monitor for material increases | £408K provision is stable but material; understand nature and likelihood of crystallisation |
| Capital expenditure | Track annual capex vs. depreciation | FY2025 capex (£302K) exceeds depreciation (£392K charge but includes disposal adjustment); ensure asset base is being maintained |
| Dividend policy | Note dividends declared | Minimal dividends (£1,100 in FY2025) suggest profits are being retained, which is credit-positive |
| Related party transactions | Review annually | PSC is Foxgrove Securities Limited (>75% control); understand inter-company arrangements |
| Filing compliance | Ensure accounts filed by 30 Sept 2027 | Currently up to date with no overdue filings |
Additional Considerations:
- Sector risk: Medical device manufacturing and clean room technology are regulated sectors with potential for product liability exposure. The provisions may relate to product warranties or regulatory obligations.
- Concentration risk: The significant debtor increase may indicate reliance on a small number of large customers, particularly in the medical/NHS supply chain.
- Corporate structure: Foxgrove Securities Limited holds >75% of shares and voting rights. Understanding the broader group structure and any inter-company liabilities would be prudent for larger facilities.
- Employee count: Stable at 38 employees (unchanged from FY2024), suggesting no dramatic operational changes.